68Ga-PSMA PET/CT to Distinguish Brain Metastasis of Renal Cell Carcinoma From Radiation Necrosis After Stereotactic Radiosurgery.
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
01 Nov 2021
01 Nov 2021
Historique:
pubmed:
21
7
2021
medline:
16
10
2021
entrez:
20
7
2021
Statut:
ppublish
Résumé
Renal cell carcinoma (RCC) is the most common primary malignancy of the kidney. Approximately 35% of patients of RCC presents with distant metastasis at initial evaluation. CT and MRI are the mainstay imaging modalities. Distinguishing radiation necrosis from tumor progression after stereotactic radiosurgery is challenging. Herein, we present a case of a 43-year-old man with RCC who was treated with stereotactic radiosurgery for brain metastases. We want to emphasize the potential value of 68Ga-PSMA PET/CT imaging in the differential diagnosis and follow-up of tumor progression from radiation necrosis in RCC patients.
Identifiants
pubmed: 34284481
doi: 10.1097/RLU.0000000000003820
pii: 00003072-202111000-00010
doi:
Substances chimiques
Gallium Isotopes
0
Gallium Radioisotopes
0
gallium 68 PSMA-11
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
913-914Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest and sources of funding: none declared.
Références
Chakraborty PS, Kumar R, Tripathi M, et al. Detection of brain metastasis with 68 Ga-labeled PSMA ligand PET/CT: a novel radiotracer for imaging of prostate carcinoma. Clin Nucl Med . 2015;40:328–329.
Rhee H, Blazak J, Tham CM, et al. Pilot study: use of gallium-68 PSMA PET for detection of metastatic lesions in patients with renal tumour. EJNMMI Res . 2016;6:76.
Einspieler I, Tauber R, Maurer T, et al. 68 Ga–prostate-specific membrane antigen uptake in renal cell cancer lymph node metastases. Clin Nucl Med . 2016;41:e261–e262.
Tolkach Y, Goltz D, Kremer A, et al. Prostate-specific membrane antigen expression in hepatocellular carcinoma: potential use for prognosis and diagnostic imaging. Oncotarget . 2019;10:4149–4160.
Ahn T, Roberts MJ, Abduljabar A, et al. A review of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) in renal cell carcinoma (RCC). Mol Imaging Biol . 2019;21:799–807.
Zacho HD, Nielsen JB, Dettmann K, et al. Incidental detection of thyroid metastases from renal cell carcinoma using 68 Ga-PSMA PET/CT to assess prostate cancer recurrence. Clin Nucl Med . 2017;42:221–222.
Yin Y, Campbell SP, Markowski MC, et al. Inconsistent detection of sites of metastatic non-clear cell renal cell carcinoma with PSMA-targeted [ 18 F]DCFPyL PET/CT. Mol Imaging Biol . 2019;21:567–573.
Rowe SP, Gorin MA, Hammers HJ, et al. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18 F-DCFPyL PET/CT. Ann Nucl Med . 2015;29:877–882.
Raveenthiran S, Esler R, Yaxley J, et al. The use of 68 Ga-PET/CT PSMA in the staging of primary and suspected recurrent renal cell carcinoma. Eur J Nucl Med Mol Imaging . 2019;46:2280–2288.